The metabolic profile of second-generation antihistamines

Allergy: European Journal of Allergy and Clinical Immunology, Supplement

Volumn 55, Issue 60, 2000, Pages 46-52

  Nicolas, J M ^a  

^a UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; ALPRAZOLAM; AMIODARONE; AMITRIPTYLINE; ANTIHISTAMINIC AGENT; ASTEMIZOLE; BENZPHETAMINE; CARBAMAZEPINE; CAREBASTINE; CETIRIZINE; CISAPRIDE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOCHROME P450 3A4; DAPSONE; DESLORATADINE; DRUG METABOLITE; EBASTINE; EPINASTINE; ERYTHROMYCIN; FEXOFENADINE; GLYCOPROTEIN P; HISTAMINE H1 RECEPTOR ANTAGONIST; KETOCONAZOLE; LORATADINE; MIZOLASTINE; NORASTEMIZOLE; PARACETAMOL; TERFENADINE; UNINDEXED DRUG;

DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG URINE LEVEL; ENZYME ACTIVITY; FOOD DRUG INTERACTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; LIVER METABOLISM; PRIORITY JOURNAL; REVIEW;

DRUG INTERACTIONS; HEART; HISTAMINE H1 ANTAGONISTS; HUMANS; HYPERSENSITIVITY, IMMEDIATE; TREATMENT OUTCOME;

EID: 0034028690     PISSN: 01081675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. SLATER JW, ZECHNICH AD, HAXBY DG. Second-generation antihistamines, a comparative review. Drugs 1999;57:31-47.
2. GONZALEZ MA, ESTES KS. Pharmacokinetic overview of oral second-generation antihistamines. Int J Clin Pharmacol Ther 1998;36:292-300.
3. 1 antihistamines. Clin Pharmacokinet 1995;28:419-432.
4. 1-receptor antagonist therapy. Clin Pharmacokinet 1991;21:372-393.
5. MATTILA MJ, PAAKKARI H. Variations among non-sedating antihistamines: are there real differences? Eur J Clin Pharmacol 1999;55:85-89.
6. WRIGHTON SA, STEVENS JC. The human hepatic cytochrome P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21.
7. SLAUGHTFR RL, EDWARDS DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 1995;29:619-624.
8. ROBBINS DK, CASTLES MA, PACK DJ, BHARGAVA VO, WEIR SJ. Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers. Biopharm Drug Dispos 1998;19:455-463.
9. PRAKASH A, LAMB HM. Mizolastine, a review of its use in allergic rhinitis and chronic idiopathic urticaria. Biodrugs 1998;10:41-63.
10. MEULDERMANS JH, LAUWERS W, HURKMANS R, SWYSEN E, HEYKANTS J. Excretion and biotransformation of astemizole in rats, guinea-pigs, dogs, and man. Drug Dev Res 1986;8:37-51.
11. NIGHTINGALE CH. Treating allergic rhinitis with second-generation antihistamines. Pharmacotherapy 1996;16:905-906.
12. HANDLEY DA, MCCULLOUGH JR, FANG KO, WRIGHT SE, SMITH ER. Comparative antihistaminic effects of astemizole and a metabolite, norastemizole. Ann Allergy Asthma Immunol 1997;78:144.
13. GARTEIZ DA, HOOK RH, WALKER BJ, OKERHOLM RA. Pharmacokinetics and biotransformation of terfenadine in man. Arzneimittelforschung 1982;32:1185-1190.
14. YUN CH, OKERHOLM RA, GUENGERERICH FP. Oxidation of the antihistaminic drug terfenadine in human liver microsomes, role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab Dispos 1993;21:403-409.
15. LING KHJ, LEESON GA, BURMASTER SD, HOOK RH, REHM MK, CHENG LK. Metabolism of terfenadine associated with CYP3A(4) activity in human hepatic microsomes. Drug Metab Dispos 1995;23:631-636.
16. KATCHEN B, CRAMER J, CHUNG M, et al. Disposition of 14C-SCH 29851 in humans. Ann Allergy 1985;55:393.
17. YUMIBE N, HUIE K, CHEN KJ, SNOW M, CLEMENT RP, CAYEN MN. Identification of human liver cylochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Biochem Pharmacol 1996;51:165-172.
18. WISEMAN LR, FAULDS D. Ebastine, a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Drugs 1996;51:260-277.
19. 1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects. Arzneimittelforschung 1994;44:59-64.
20. HASHIZUME T, MISE M, TERAUCHI Y, et al. N-dealkylation and hydroxylation of ebastine by human liver cytochrome P450. Drug Metab Dispos 1998;26:566-571.
21. WOOSLEY RL, CHEN Y, FREIMAN JP, GILLIS RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993;269:1532-1536.
22. HONIG PK, WORTHAM DC, ZAMANI K, CONNER DP, MULLIN JC, CANTILENA LR. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 1993;269:1513-1518.
23. HONIG PK, WORTHAM DC, ZAMANI K, CANTILENA LR. Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters. Drug Invest 1994;7:148-156.
24. HONIG PK, WORTHAM DC, HULL R, ZAMANI K, SMITH JE, CASTILENA LR. Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J Clin Pharmacol 1993;33:1201-1206.
25. FOURNIER P, PACOURET G, CHARBONNIER B. A new cause of torsade de pointes: combination of terfenadine and troleandomycin. Ann Cardiol Angeiol (Paris) 1993;42:249-252.
26. MARCHIANDO RJ, COOK MD, JUE SG. Probable terfenadine-fluoxetine-associated cardiac toxicity. Ann Pharmacother 1995;29:937-938.
27. HONIG PK, WORHAM DC, ZAMANI K, MULLIN JC, CONNER DP, CANTILENA LR. The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. Clin Pharmacol Ther 1993;53:630-636.
28. AWNI WN, CAVANAUGH JH, LEESE P, et al. The pharmacokinetic and pharmacodynamic interaction between zileuton and terfenadine. Eur J Clin Pharmacol 1997;52:49-54.
29. CRAFT TM. Torsade de pointes after astemizole overdose. BMJ 1986;292:660.
30. SNOOK J, BOOTHMAN BD, WATKINS J, COLLINS JD. Torsade de pointes ventricular tachycardia associated with astemizole overdose. Br J Clin Pract 1988;42:257-259.
31. TSAI WC, TSAI LM, CHEN JH. Combined use of astemizole and ketoconazole resulting in torsade de pointes. J Formos Med Assoc 1997;96:144-146.
32. GOOS JE, RAMO BW, BLAKE K. Torsade de pointes associated with astemizole (hismanal) therapy. Arch Intern Med 1993;153:2705.
33. VORPERIAN VR, ZHOU Z, MOHAMMAD S, HOON TJ, STUDENIC C, JANUARY CT. Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole. J Am Coll Cardiol 1996;28:1556-1561.
34. 1 antihistamines: a roundtable discussion. Kenilworth, NJ: Schering Plough, 1996:14-21.
35. BRANNAN MD, REIDENBERG P, RADWANSKI E, et al. Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations. Clin Pharm Ther 1995;58:269-278.
36. CARR RA, EDMONDS A, SHI H, et al. Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration. Anlimicrob Agents Chemother 1998;42:1176-1180.
37. 1 antihistamine. Clin Exp Allergy 1999;29:206-211.
38. HORAK F, STUBNER UP. Comparative tolerability of second generation antihistamines. Drug Saf 1999;20:385-401.
39. DU BUSKF LM. Second-generation antihistamines: the risk of ventricular arrhythmia. Clin Ther 1999;21:281-295.
40. SPENCER CM, FAUDS D, PETTER DH. Cetirizine, a reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders. Drugs 1993;46:1055-1080.
41. SALE M, WOOSLEY RL, THAKKER K, PHILLIPS K, CARIDI F, CHUNG M. Effects of cetirizine and erythromycin, alone and in combination, on QT interval and pharmacokinetics in healthy subjects. Ann Allergy Asthma Immunol 1996;76:93.
42. SALE M, WOOSLEY R, THAKKER K, PHILLIPS K, CARIDI F, CHUNG M. A randomized, placebo-controlled, multiple-dose study to evaluate the electrocardiographic and pharmacokinetic interactions of azithromycin and cetirizine. Ann Allergy Asthma Immunol 1996;76:93.
43. 1-RA) cetirizine (CET) in patients with chronic urticaria. Pharm Res 1993;10:S355.
44. RIDOUT SM, TARIQ SM. Cetirizine overdose in a young child. J Allergy Clin Immunol 1997;99:860-861.
45. SALE ME, BARBEY JT, WOOSLEY RL, et al. The electrocardiographic effects of cetirizine in normal subjects. Clin Pharmacol Ther 1994;56:295-301.
46. MARKHAM A, WAGSTAFF AJ. Fexofenadine. Drugs 1998;55:269-274.
47. 1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res Commun Mol Pathol Pharmacol 1997;98:273-292.
48. PRATT CM, MASON J, RUSSELL T, AHLBRANDT R. Effect of fexofenadine HCl on corrected QT interval (QTc). Allergy 1997;52 Suppl 37:67.
49. PRATT CM, MASON J, RUSSELL T, REYNOLDS R, AHLBRANDT R. Cardiovascular safety of fexofenadine HCl. Am J Cardiol 1999;83:1451-1454.
50. OHTANI H, KOTAKI H, SAWADA Y, IGA T. A comparative pharmacokinetic-pharmacodynamic study of the electrocardiographic effects of epinastine and terfenadine in rats. J Pharm Pharmacol 1997;49:458-462.
51. HORN JR, HANSTEN PD. Drug interactions with antibacterial agents. Fam Pract 1995;41:81-90.
52. JHA RJ. Thiazolidinediones, the new insulin enhancers. Clin Exp Hypertens 1999;21:157-166.
53. GRANBERRY MC, SCHNEIDER EF, FONSECA VA. The role of troglitazone in treating the insulin resistance syndrome. Pharmacotherapy 1998;18:973-987.
54. BAILEY DG, MALCOLM J, ARNOLD O, SPENCE JD. Grapefruit juice drug interactions. Br J Clin Pharmacol 1998;46:101-110.
55. BENTON RE, HONIG PK, ZAMANI K, CANTILENA LR, WOOSLEY RL. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther 1996;59:383-388.
56. HONIG PK, WORTHAM DC, LAZAREV A, CANTILENA LR. Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine. J Clin Pharmacol 1996;36:345-351.
57. SPENCER JD. Drug interactions with grapefruit: whose responsibility is it to warn the public? Clin Pharmacol Ther 1997;61:395-400.
58. RAEISSI SD, GUO Z, DOBSON GL, ARTURSSON P, HIDALGO IJ. Comparison of CYP3A activities in a subclone of Caco-2 cells (TC7) and human intestine. Pharm Res 1997;14:1019-1025.
59. ZHAO XJ, YOKOYAMA H, CHIBA K, WANWIMOLRUK S, ISHIZAKI T. Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450. J Pharmacol ExpTher 1996;279:1327-1334.
60. Food and Drug Administration. Labeling guidance for astemizole tablets, 1997.
61. SHIMADA T, YAMAZAKI H, MIMURA M, INUI Y, GUENGUERICH FP. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes from 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-423.
62. HONIG PK, SMITH JE, WORTHAM DC, ZAMANI K, CANTILENA LR. Population variability in the pharmacokinetics of terfenadine: the case for a pseudo-polymorphism with clinical implication. Drug Metab Drug Interact 1994;11:161-168.
63. MATZE GR, HALSTENSON CE, OPSAHL JA, et al. Pharmacokinetics of loratadine in patients with renal insufficiency. J Clin Pharmacol 1990;30:364-371.
64. GAEDIGK A, BLUM M, GAEDIGK R, EICHELBAUM M, MEYER UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 1991;48:943-950.
65. NICOLAS JM, WHOMSLEY R, COLLART P, ROBA J. In vitro inhibition of human liver drug metabolizing enzymes by second generation antihistamines. Chem Biol Interact 2000 (in press).
66. 1 receptor antagonists. Drug Metab Dispos 1998;26:536-539.
67. HU YP, ROBERT J. Azelastine and flezelastine as reversing agents of multidrug resistance: pharmacological and molecular studies. Biochem Pharmacol 1995;50:169-175.
68. RAMU A, RAMU N. Reversal of multidrug resistance by phenothiazines and structurally related compounds. Cancer Chemother Pharmacol 1992;30:165-173.
69. HAIT WN, GESMONDE JF, MURRIN JR, YANG JM, CHEN HX, REISS M. Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells. Biochem Pharmacol 1993;45:401-406.
70. MURPHY MP, OWEN R, BERNSTEIN LA, SCHMIDT KH. Modulation of the MDR phenotype in doxorubicin-resistant MCF7 breast carcinoma cells using lerfenadine and ketoconazole. Clin Pharmacol Ther 1995;57:174.
71. FISHER GA, LUM BL, HAUSDORFF J, SIKIC BI. Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer 1996;32:1082-1086.
72. SCHWARZ UI, KRAPPWEIS J, OFRTEL R, GRAMATTE T, KIRCH W. The erythromycin-talinolol interaction increases oral bioavailability in humans. Eur J Clin Pharmacol 1998;55:A23.
73. SCHUETZ EG, BECK WT, SCHUETZ JD. Modulators and substrates of P-glycoprotein and eytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996;49:311-318.